These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11926874)

  • 41. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient.
    Soler Palacin P; Aramburo A; Moraga FA; Cabañas MJ; Figueras C
    Pediatr Infect Dis J; 2006 Apr; 25(4):382. PubMed ID: 16568000
    [No Abstract]   [Full Text] [Related]  

  • 44. HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore.
    Goh KS; Kapoor R; Lee CC; Ng CY; Leong KP
    Ann Acad Med Singap; 2019 Apr; 48(4):133-138. PubMed ID: 31131386
    [No Abstract]   [Full Text] [Related]  

  • 45. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 46. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 47. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
    Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
    Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.
    Frissen PH; de Vries J; Weigel HM; Brinkman K
    AIDS; 2001 Jan; 15(2):289. PubMed ID: 11216946
    [No Abstract]   [Full Text] [Related]  

  • 49. Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK.
    Sadiq ST; Pakianathan M
    Sex Transm Infect; 2007 Jun; 83(3):181-2. PubMed ID: 17098765
    [No Abstract]   [Full Text] [Related]  

  • 50. Abacavir hypersensitivity reaction predicted by genetic test.
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Screening for abacavir hypersensitivity.
    Deresinski S
    AIDS Alert; 2007 Dec; 22(12):140-1. PubMed ID: 18411482
    [No Abstract]   [Full Text] [Related]  

  • 52. Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivity.
    Albrecht H
    AIDS Clin Care; 2007 Oct; 19(10):81-2. PubMed ID: 18398994
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacogenomics testing for type B adverse drug reactions to anti-infective drugs: the example of hypersensitivity to abacavir.
    Agundez JA; Esguevillas G; Amo G; Garcia-Martin E
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):151. PubMed ID: 25891395
    [No Abstract]   [Full Text] [Related]  

  • 54. In Mexican Mestizos the HCP5 rs2395029 SNP may be a genetic marker for screening abacavir hypersensitivity.
    Sanchez-Giron F; Carnevale A
    Pharmacogenomics; 2012 Feb; 13(3):251-2. PubMed ID: 22304575
    [No Abstract]   [Full Text] [Related]  

  • 55. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
    Phillips EJ
    Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
    [No Abstract]   [Full Text] [Related]  

  • 56. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study).
    Arrizabalaga J; Rodriguez-Alcántara F; Castañer JL; Ocampo A; Podzamczer D; Pulido F; Riera M; Sanz J; Pascual-Bernaldez M; Dal-Re R;
    HIV Clin Trials; 2009; 10(1):48-51. PubMed ID: 19362996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [New variations in highly active antiretroviral therapy. Simple combination as a promising option].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():50-2. PubMed ID: 10863312
    [No Abstract]   [Full Text] [Related]  

  • 59. Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population.
    Badulli C; Sestini R; Sbarsi I; Baroncelli M; Pizzochero C; Martinetti M; Porfirio B
    Pharmacogenomics; 2012 Feb; 13(3):247-9. PubMed ID: 22304574
    [No Abstract]   [Full Text] [Related]  

  • 60. Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?
    Bracciale L; Santangelo R; Fanti I; Prosperi M; Colafigli M; Di Giambenedetto S; Marchetti S; Di Franco A; Cauda R; De Luca A
    Antivir Ther; 2009; 14(1):99-101. PubMed ID: 19320242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.